Saturday, October 17, 2026

 

One-step rapid syphilis test detects infection earlier, researchers report



Layered nanoparticle gives rapid tests better chance at detecting syphilis, on the rise in the U.S., at its earliest stages




Penn State

Rapid syphilis test multilayered nanoparticle

image: 

A new pilot rapid test for syphilis from a team led by Penn State researchers integrates two blood tests into one and detects bacteria at very low levels to detect the disease in its earliest stages.

view more 

Credit: Pan Research Lab





UNIVERSITY PARK, Pa. — Penicillin has cured syphilis cases since 1943, but symptoms for the sexually transmitted infection, known as "the great imitator," mimic many other diseases and can come and go without treatment while the infection keeps causing harm. If it remains undetected, it can spread to partners and to babies during pregnancy, causing lifelong effects. A new rapid test developed by a team led by Penn State researchers detects lower levels of the two types of antibodies the body makes to fight the syphilis bacteria and respond to disease-related cell damage, potentially leading to earlier interventions and fewer appointments for patients. 

Key to the advancement are the nanoparticles that accumulate and form the visible line for a positive result on most diagnostic tests, according to corresponding author Dipanjan Pan, Penn State’s Dorothy Foehr Huck & J. Lloyd Huck Chair Professor in Nanomedicine. The team’s new pilot testing device, published in a study in ACS Sensors, swapped the typical gold nanoparticle for one layered in silver and sealed in more gold to produce test lines 19% to 46% stronger than those of comparable devices while reliably detecting lower concentrations of antibodies.

“The low-titer range, meaning the range with the lowest concentration of antibodies, is particularly challenging for detecting syphilis,” Pan said. He added that nanoparticles accumulate into a visible line as they bind to more and more antibodies in a sample flowing through the device. “This range is also clinically important, occurring during early infection, later stages of syphilis or after treatment when antibody levels are declining to make sure treatment worked.”

In the diagnostic pathway established by the U.S. Centers for Disease Control and Prevention (CDC), the first “treponemal” blood test detects antibodies against the syphilis bacteria, Treponema pallidum. These antibodies stay in the body for decades, and a patient who received treatment years ago will still test positive as long as the antibodies remain in their system. The second “non-treponemal test” looks for separate antibodies created in response to cellular damage, indicating the stage of infection and whether a person needs treatment.

Running both tests lessens the chance for false-negative or false-positive results and gives doctors a better sense for whether the disease occurred in the past, is currently active or has been properly treated, according to the CDC. 

“What is important about our approach is that we are not asking clinicians to abandon this well-established diagnostic pathway,” Pan said. “Instead, we are trying to reproduce the same sequence of diagnostic information in a much faster and potentially point-of-care format.”

The limitation to this point, he explained, was not the ability to detect the antibodies but the ability for clinicians to see the gold nanoparticles that only become visible to the naked eye when enough of them accumulate. One way to make them “brighter” was to increase their size. However, around 60 nanometers, roughly 100 times smaller than a red blood cell, they start clumping or settling like sand in a river rather than flowing through the device.

The team instead altered the nanoparticle’s composition. According to Pan, particles behave differently on the nanoscale, and the electrons of gold atoms in nanoparticles interact collectively and absorb wavelengths of light differently. This gives them the ruby-red color commonly seen in rapid tests instead of gold’s characteristic hue.

“At the nanoscale, I like to picture the electrons on the particle’s surface as the ripple of standing and sitting that happens when a stadium full of people participate in ‘the wave,’” said first author Ketan Dighe, a Penn State biomedical engineering graduate student. “That collective motion is called localized surface plasmon resonance, and when light hits them, it’s what gives the particles their color and makes them so useful for detection.”

When a particle has multiple metallic layers, Dighe added, the electrons that would typically only interact with other electrons from the same layer, or “plasmon,” start to collectively combine features across the metallic boundaries, creating a much stronger optical signal. The team sandwiched a layer of silver, which has stronger optical properties than gold but degrades quickly when exposed to oxygen, between two layers of gold. This kept the particle stable while taking advantage of the silver and the resulting combined features from multiple metallic layers.

Pan likened the resulting stronger optical properties to another collective human activity: a choir.

“One singer can be heard, but when several singers are carefully coordinated, their voices emphasize one another and the sound becomes much more powerful,” Pan said. Those three layers work together to produce a much stronger optical signal than the original gold particle alone.”

Prior to embedding the nanoparticles in a lateral flow reporter — the typical set up of at-home detection tests, like those used for pregnancy or COVID-19 — the team first compared the optical performance of the multilayer nanoparticles to conventional gold. In these laboratory benchmark tests, the team found six times fewer multilayer particles were needed to form a visible mark than gold alone. The multilayer particles also remained visible with three times fewer sample target molecules, an encouraging sign that they would be able to detect syphilis antibodies in low concentrations, according to Pan.

The team then tested the nanoparticles using 36 clinical specimens spanning a range of antibody concentrations from the CDC and Boca Biolistics, a commercial biorepository. In these experiments, line intensities increased 19% to 46% compared to conventional gold nanoparticles. The largest gains were found in tests detecting antibodies in the lowest concentrations.

In practice, that sensitivity would give healthcare professionals vital information to determine treatment options before a patient leaves the clinic, according to co-investigator Casey Pinto, a clinician and associate professor of public health sciences at Penn State College of Medicine. 

“If I could tell a patient what infection they had during a visit, the counseling, the information I provide and the treatment would dramatically change,” Pinto said.

Nearly 4,000 babies in the U.S were born with syphilis in 2024, the 12th consecutive annual increase. The CDC reported that a lack of timely testing and adequate treatment contributed to nearly 90% of these congenital cases.

“Syphilis is one of those unique bacteria that can impact every single organ of the body,” Pinto said. “If we do not catch syphilis and the woman is pregnant, it could infect the child, too. The baby can be born with developmental delays, heart problems, blindness, teeth and bone malformations, skin rashes and it can even lead to death.”

Two rapid tests for syphilis have been approved by the U.S. Food and Drug Administration in recent years, but they only detect treponemal antibodies. According to Pan, there are currently no single-step confirmatory syphilis tests approved for use in the U.S. One exists in Europe, but it does not detect antibodies in the low-titer range. 

He said the team applied for a patent for the device and is exploring opportunities to partner with industry as they move towards larger validation studies, further prototype development and regulatory submission. 

“We could potentially move syphilis testing from a multistep laboratory process toward a model of testing, diagnosing and treating in a single clinical visit,” he said.

Other Penn State authors include biomedical engineering doctoral students Ketan Dighe, Shraddha Krishnakumar and Nivetha Gunaseelan; Satheesh Natarajan, postdoctoral researcher in nuclear engineering; and recent doctoral recipients David Skrodzki, in materials science and engineering, and Matthew Molinaro, in engineering science and mechanics. From Louisiana State University, authors include Manas Ranjan Gartia, associate professor of mechanical and industrial engineering, and mechanical and industrial engineering doctoral student Maria Iftesum.

This study was supported by the National Institutes of Health's National Institute of Allergy and Infectious Diseases under award R01AI185115 and National Heart, Lung, and Blood Institute under award R01HL173540; the CDC under award 75D30122C15492; the U.S. National Science Foundation under award CBET 2153091/2229986; and the Department of Defense Congressionally Directed Medical Research Program under award TP210376. This content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.

At Penn State, researchers are solving real problems that impact the health, safety and quality of life of people across the commonwealth, the nation and around the world.

For decades, federal support for research has fueled innovation that makes our country safer, our industries more competitive and our economy stronger. Recent federal funding cuts threaten this progress.

Learn more about the implications of federal funding cuts to our future at Research or Regress.

 

USF study finds persistent gaps in hearing aid coverage, especially for older and lower-income adults



Newly published findings in JAMA Otolaryngology–Head & Neck Surgery show substantial differences in mandated coverage across age groups



University of South Florida

Michelle Arnold University of South Florida -- credit USF

image: 

Michelle Arnold, associate professor, University of South Florida’s Department of Communication Sciences and Disorders

view more 

Credit: University of South Florida






Tampa, Fla. (Oct. 16, 2026) -- Despite gradual progress in insurance policies requiring hearing aid coverage, many Americans still lack guaranteed access to these essential devices, according to a new study published in JAMA Otolaryngology–Head & Neck Surgery.

The study found substantial differences in mandated coverage across age groups, with the greatest increase among children and the most persistent gaps among older adults.

Titled “Longitudinal Growth of Mandated Hearing Aid Benefits in the US,” the study analyzed data from more than 50 million people to examine hearing aid coverage requirements across private insurance, Medicaid and federal programs serving veterans and military families.

Michelle Arnold, an audiologist and associate professor in the University of South Florida’s Department of Communication Sciences and Disorders, led the research with colleagues from the University of Missouri, Columbia; Georgia State University; the University of California, Irvine; and the University of Texas at San Antonio.

“Adults covered by Medicare and those living in households experiencing poverty are largely left out of gains in hearing aid insurance coverage that we've seen over the past 20 years,” Arnold said. “This is problematic, because we know that hearing aids can help reduce risks for serious health conditions such as cognitive decline, falls, hospitalizations and mental health problems.”

Without insurance coverage, the cost of prescription hearing aids can be a substantial barrier. Average out-of-pocket costs range from $2,000 to $7,000 per set.

Coverage gains vary by age

Coverage gains differed substantially by age, with children and working-age adults seeing increases while older adults experienced a decline.

  • The percentage of children younger than 18 with mandated hearing aid coverage increased from 34.1% in 2008 to 52.5% in 2023.
  • Among adults ages 18 to 64, the percentage nearly doubled, rising from 10.2% to 19.2%.
  • The percentage of adults ages 65 and older with mandated hearing aid coverage declined from 18.5% in 2008 to 16.9% in 2023. 

Medicaid was the largest contributor to mandated coverage in both children and working-age adults, underscoring the program’s role in expanding access to hearing care. Traditional Medicare does not cover hearing aids, and benefits offered through Medicare Advantage plans vary by plan, leaving many older adults without guaranteed coverage.

The findings also highlight a potential coverage gap as children transition into adulthood.

“Children may benefit from federal Medicaid protections or state laws requiring private insurers to cover hearing aids, but those protections may not continue as they age into adult coverage,” said Arnold.

Financial barriers persist

The study also found differences in mandated coverage based on household income and housing status.

In 2023, people living in households below the federal poverty level were more likely to have mandated hearing aid coverage than those with higher incomes. Renters were also more likely than homeowners to have mandated coverage across all three age groups. These patterns reflect Medicaid’s role as a major source of hearing aid benefits.

Yet greater access relative to other groups did not mean that lower-income adults were adequately covered. Among adults living in households below the federal poverty level, 63.5% of those ages 18 to 64 and 71.3% of those 65 and older lacked mandated hearing aid coverage.

Policy changes could expand access

The researchers identified several opportunities to improve access to hearing aids, including expanding Medicaid benefits for adults, requiring private insurance plans to cover hearing aids and establishing guaranteed hearing benefits under Medicare.

The study was supported by the National Institute on Deafness and Other Communication Disorders of the National Institutes of Health.

 

Wider approach needed to mitigate rising rechargeable battery emissions



A new University of Melbourne-led study has identified new insights and evidence that could help significantly mitigate the fast-rising climate impact of Lithium-ion Batteries (LIBs)



University of Melbourne






A new University of Melbourne-led study has identified new insights and evidence that could help significantly mitigate the fast-rising climate impact of Lithium-ion Batteries (LIBs).

Electric vehicle batteries are crucial to clean energy, but production emissions are significant. Most LIB decarbonisation research has focused on reducing emissions from the supply chain, including sourcing and refining raw materials, manufacturing and end-of-life recycling.

The study’s modelling found that by 2050, demand for LIBs used in electric cars, vans, buses, trucks and battery energy storage systems could rise twentyfold, leading to a tenfold increase in their supply-chain greenhouse gas emissions. The research also identified ways to reduce global LIB emissions on par to the annual emissions of the EU.

Published in Cell Press' flagship sustainability journal One Earth, the research, led by University of Melbourne Associate Professor Wen Li, found that cleaner production alone was not enough to mitigate the resulting annual LIB supply chain emissions.

“Encompassing demand-side decarbonisation strategies, such as reducing battery sizes, extending battery lifetimes and promoting shared mobility, could help reduce the predicted global carbon dioxide (CO₂)-equivalent LIB emissions over that period to 2050 by around half,” said Associate Professor Li, from the Faculty of Engineering and Information Technology.

The study, with researchers from the Chinese Academy of Sciences and the University of Sheffield, was one of the first detailed global assessments to examine both supply-side and demand-side factors.

It was the first to examine several demand-side strategies for reducing impact on the global LIB supply chain and directly compare these contributions with ambitious supply-side decarbonisation efforts that could be introduced over time.

The global supply chain modelling covered battery material production, component production, battery manufacturing, and end-of-life treatment from 2024 through to 2050.

On the supply-side, cleaner production, such as switching battery chemistries, greener factories and recovering materials from used batteries, was essential, but not enough to mitigate predicted emissions increases over that time.

On the demand side, through battery technology advancement and business model innovation, researchers modelled how many batteries will be needed, what size, their longevity and replacement need, through to 2050. If mitigated, all four factors could help reduce the number of new batteries needed significantly around the globe for transport and energy storage.

Corresponding author Associate Professor Li said while cleaner production helped, reducing demand was “another very large mitigation opportunity”.

He said supply-side decarbonisation remained essential; cleaner electricity was especially important and recycling increasingly valuable. But, he added, without the additional measures tested, the global battery supply chain could generate around 19–23 billion tonnes of CO₂-equivalent emissions through to 2050.

“Combining ambitious supply- and demand-side strategies cuts this to around 9–12 billion tonnes – roughly half,” Associate Professor Li said. “Within that overall reduction, supply-side measures account for around 3.5–4.7 billion tonnes of mitigation, while demand-side strategies account for around 6–7 billion tonnes,” Associate Professor Li said.

“These are emissions reductions on the scale of the annual emissions of a major global economy such as the EU.”

Lead and first author Dr Haiwei Zhou, also from the Faculty of Engineering and Information Technology, said the team now hoped to improve the model’s regional resolution, as mining, refining, electricity and environmental pressures varied greatly between locations.

“We also want to test whether the same supply-versus-demand dynamic appears in other rapidly growing clean-energy supply chains such as wind turbines and solar panels,” Dr Zhou said. “For policy and industry, battery decarbonisation should move beyond regulating production emissions alone.”

Co-author Professor Prakash Singh from the University of Melbourne Faculty of Business and Economics agreed that new policies could help.

“Policies can also encourage longer battery lifetimes, appropriate battery sizing, higher utilisation and second-life applications,” Professor Singh said. “The broader question should be not only ‘How low is the carbon footprint of each battery?’, but also ‘How much battery capacity do we actually need to provide the service?’”

 

Ethnic inequalities in stroke explained by differences in stroke risk factors





King's College London






Stroke risk is primarily linked to differences in traditional stroke risk factors, like diabetes and high blood pressure, rather than ethnicity, according to findings from a new South London study conducted at King’s College London.  

The research found that while Asian and Black individuals were more likely to have diabetes or hypertension than White individuals, the likelihood of someone having a stroke once they had these conditions was similar across ethnic groups. 

Although previous research has consistently shown higher rates of stroke in some ethnic groups and has identified hypertension and diabetes as important contributors to these inequalities, the role of ethnicity on the risk of stroke has remained controversial.  

The King’s College London study – funded by King’s Health Partners, Guy's & St Thomas's Charity and the National Institute for Health and Care Research (NIHR) – set out to examine this relationship in more detail by looking separately at the development of cardiometabolic risk factors and the subsequent progression from these conditions to stroke.   

Published in BMC Public Health, the study analysed primary care electronic records from more than 650,000 people in South London, collected from 41 GP practices in Lambeth between 2005 and 2021. The study included patients of Asian, Black and White ethnicity and examined three major risk factors for stroke: hypertension (high blood pressure), diabetes and hypercholesterolaemia (high levels of cholesterol in the blood). 

To study the relationship between ethnicity, the cardiometabolic risk factors and stroke, the researchers used a modelling technique called a ‘multistate analysis.’  

This technique allows researchers to analyse how an individual moves through different health events or ‘states’ over time – in this case moving from having no risk factors, to having one of the risk factors, and then on to having a stroke. Using this method, the researchers calculated the probability of individuals moving from one state to the next.  

As the researchers expected, the occurrence of stroke risk factors was higher in Black and Asian patients than in White patients. Ethnicity was significantly associated with the probability of developing all three stroke risk factors, especially diabetes and hypertension. Compared with White patients, Black patients were around twice as likely to develop hypertension and more than twice as likely to develop diabetes. Asian patients were about 50% more likely to get hypertension and were three times as likely to get diabetes than White patients.  

However, when the researchers looked at the transition from stroke risk factor to stroke itself, these patterns disappeared. Among patients with hypertension or diabetes, Black and Asian ethnicity did not confer a higher probability of progressing to stroke than that observed in White patients with the same conditions. The authors say this finding confirms that ethnic inequalities in stroke incidence are primarily associated with the cardiometabolic risk factors. 

Dr Marc Delord, Research Fellow in Medical Statistics at King’s College London, said: “We know that stroke occurs more frequently in some ethnic groups. Our study explains that these inequalities are attributable to traditional modifiable cardio-metabolic risk factors only: Although Black and Asian patients were more likely to develop these risk factors, particularly hypertension and diabetes, once these conditions are present, their subsequent probability of stroke was not higher than that of White patients. 

“Our findings reinforce the need for prevention, detection and management strategies that account for the higher burden of these modifiable risk factors observed in Black and Asian populations, including culturally tailored lifestyle interventions, to help reduce inequalities in stroke risk.” 

Professor Abdel Douiri, Professor of Medical Statistics and Clinical Trials at King’s College London and co-author of the paper, added: “These findings underscore a clear message: reducing ethnic disparities in stroke requires addressing the underlying inequalities in the prevention, early detection, and effective management of hypertension and diabetes, which disproportionately affect Black and Asian communities.” 

Hypercholesterolaemia did not fit the same pattern as the other risk factors. Among Black patients with hypercholesterolaemia, the study identified a slight increase in the subsequent likelihood of stroke compared with White patients. The authors say this finding needs further investigation.  

Previous research recently published in BMC Medicine from the team in the same study population found that Black patients with hypercholesterolaemia were less likely to receive statin treatment. Although data on medication prescribing were not included in the current study, the researchers would like to investigate whether the reduced prescribing of statins could help to explain the increased occurrence of stroke observed in this population.